Home  »  Business   »  The Business Case For Buying Aytu BioPharma Inc. (...

The Business Case For Buying Aytu BioPharma Inc. (NASDAQ: AYTU) Stock Now

Aytu BioPharma Inc. (NASDAQ:AYTU) price closed lower on Tuesday, July 05, dropping -0.30% below its previous close.

A look at the daily price movement shows that the last close reads $0.67, with intraday deals fluctuated between $0.621 and $0.74. The company’s 5Y monthly beta was ticking -0.39. Taking into account the 52-week price action we note that the stock hit a 52-week high of $5.14 and 52-week low of $0.45. The stock added 15.17% on its value in the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Aytu BioPharma Inc., which has a market valuation of $26.52 million, is expected to release its quarterly earnings report Feb 09, 2022 – Feb 14, 2022. Analysts tracking AYTU have forecast the quarterly EPS to shrink by -0.41 per share this quarter, while the same analysts predict the annual EPS to hit -$2.36 for the year 2022 and up to -$0.91 for 2023. In this case, analysts estimate an annual EPS growth of 30.40% for the year and 61.40% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $24.8 million, with the likely lows of $24.8 million and highs of $24.8 million. Staying with the analyst view, there is a consensus estimate of $94.5 million for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow 44.00% above that which the company brought in 2022.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give AYTU a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

The overview shows that AYTU’s price is at present 24.48% off the SMA20 and 19.29% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 64.11, with weekly volatility standing at 21.79%. The indicator jumps to 14.08% when calculated based on the past 30 days. Aytu BioPharma Inc. (NASDAQ:AYTU)’s beta value is holding at -0.33, while the average true range (ATR) indicator is currently reading 0.08.

An analysis of the Aytu BioPharma Inc. (NASDAQ:AYTU) stock in terms of its daily trading volume indicates that the 3-month average is 1.19 million. However, this figure increases on the past 10-day timeline to an average of 0.88 million.

Current records show that the company has 29.69M in outstanding shares. The insiders’ percentage holdings are 0.30% of outstanding shares while the percentage share held by institutions stands at 16.40%. The stats also highlight that short interest as of Apr 28, 2022, stood at 1.68 million shares, which puts the short ratio at the time at 0.72. From this we can glean that short interest is 5.04% of company’s current outstanding shares. Notably, we see that shares short in April rose slightly given the previous month’s figure stood at 1.66 million. But the -50.52% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]